Chromadex Corp (NASDAQ:CDXC)

Delayed Data
As of Feb 01
 -0.01 / -0.48%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Contact Information

Chromadex Corp.
10900 Wilshire Boulevard
Los Angeles California 90024
P:(310) 388-6706
Investor Relations:
(949) 344-3782



Mutual fund holders4.83%
Individual stakeholders28.86%
Other institutional11.75%

Top Executives

Robert N. FriedChief Executive Officer & Director
Brianna GerberChief Financial Officer
Ryan DellingerDirector-Scientific Affairs
Fadi KaramChief Marketing Officer
Trent CraneRegional Vice President-Sales